These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38957938)

  • 1. Adverse events following immunization of co- and separate administration of DTaP-IPV/Hib vaccines: A real-world comparative study.
    Zhu Y; Sun L; Wang Y; Wang J; Wang Y; Li J; Wang L; Guo Y
    Hum Vaccin Immunother; 2024 Dec; 20(1):2372884. PubMed ID: 38957938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, controlled, multicenter study of the immunogenicity and safety of a fully liquid combination diphtheria-tetanus toxoid-five-component acellular pertussis (DTaP5), inactivated poliovirus (IPV), and haemophilus influenzae type b (Hib) vaccine compared with a DTaP3-IPV/Hib vaccine administered at 3, 5, and 12 months of age.
    Vesikari T; Silfverdal SA; Boisnard F; Thomas S; Mwawasi G; Reynolds D
    Clin Vaccine Immunol; 2013 Oct; 20(10):1647-53. PubMed ID: 23966556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
    Johns TL; Hutter GE
    Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
    Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
    Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan.
    Nakayama T; Vidor E; Tsuzuki D; Nishina S; Sasaki T; Ishii Y; Mizukami H; Tsuge H
    J Infect Chemother; 2020 Jul; 26(7):651-659. PubMed ID: 32307307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance for adverse events following immunization with DTaP-containing combination vaccines in Linping, China, 2019-2022.
    Chen Q; Zhang C; Ye C; Zhu J; Shen J; Zhu C; Yang P; Liu T; Xu Y
    Front Public Health; 2024; 12():1278513. PubMed ID: 38596516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination.
    Rennels MB; Englund JA; Bernstein DI; Losonsky GA; Anderson EL; Pichichero ME; Munoz FM; Wolff MC
    Pediatr Infect Dis J; 2000 May; 19(5):417-23. PubMed ID: 10819337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines.
    Dolhain J; Janssens W; Dindore V; Mihalyi A
    Expert Rev Vaccines; 2020 May; 19(5):419-443. PubMed ID: 32419537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants.
    Zepp F; Schuind A; Meyer C; Sänger R; Kaufhold A; Willems P
    Pediatrics; 2002 Apr; 109(4):e58. PubMed ID: 11927731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
    Melo FIR; Morales JJR; De Los Santos AHM; Rivas E; Vigne C; Noriega F
    Pediatr Infect Dis J; 2017 Jun; 36(6):602-608. PubMed ID: 28067718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and reactogenicity of diphtheria, tetanus and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine.
    Knutsson N; Trollfors B; Taranger J; Bergfors E; Sundh V; Lagergård T; Ostergaard E; Cicirello H; Käyhty H
    Vaccine; 2001 Aug; 19(31):4396-403. PubMed ID: 11483264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting.
    Lim FS; Phua KB; Lee BW; Quak SH; Teoh YL; Ramakrishnan G; Han HH; Van Der Meeren O; Jacquets JM; Bock HL
    Southeast Asian J Trop Med Public Health; 2011 Jan; 42(1):138-47. PubMed ID: 21323176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine.
    Xu J; Stek JE; Ziani E; Liu GF; Lee AW
    Pediatr Infect Dis J; 2019 Apr; 38(4):439-443. PubMed ID: 30882742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines.
    Schmitt HJ; von Kries R; Hassenpflug B; Hermann M; Siedler A; Niessing W; Clemens R; Weil J
    Pediatr Infect Dis J; 2001 Aug; 20(8):767-74. PubMed ID: 11734739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the safety of diphtheria, tetanus and acellular pertussis containing combination vaccines in Chengdu, 2015-2019].
    Li L; Yang RP; Cai J; Zheng JH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):958-962. PubMed ID: 32907285
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017.
    Li Z; Xu J; Tan H; Zhang C; Chen J; Ni L; Yun X; Huang Y; Wang W
    Int J Infect Dis; 2020 Oct; 99():149-155. PubMed ID: 32795602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.